Global

Value frameworks are now "sexy". In the US, no fewer than five have emerged since around 2015. Leela Barham discusses how the value assessment landscape is evolving.

The Association of the British Pharmaceutical Industry has sought permission for a Judicial Review of the National Institute for Health and Care Excellence’s unpopular changes to tackle drug affordability.

The Association of the British Pharmaceutical Industry is seeking permission for a Judicial Review of NICE's affordability proposals. Leela Barham reports.

Branded generics in select emerging markets can offer above-market returns, writes Renaud Savary.

Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

Lana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.

Outlining the new leadership and C-level roles of tomorrow needed to take on the disruption event on pharma's horizon.

Last week’s EFPIA and EU Health Council annual conferences highlighted the growing divisions-and resentments-between industry and governments on drug pricing. Reflector reports.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

No one thought Brexit would be easy and in the wake of last week's UK election the going has only gotten tougher. Leela Barham looks at the fallout from a life sciences perspective.

With the UK's General Election set for June 8, Leela Barham looks what the competing parties are promising for pharma and healthcare

Several interventions and developments across the continent likely to keep discussions around drug affordability on high burn.

Although the local pharma and biotech sectors in Taiwan have yet to emulate the success story of its semiconductor industry, companies in the life sciences have reached a solid level of maturity, notably driven by the substantial investments injected by Taiwan’s successive governments over the past two decades.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector.